Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
8-KReport of unscheduled material events or corporate eventMay 18, 2001View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionMay 10, 2001View HTMLDownload DOCDownload PDF
DEFA14AAdditional proxy soliciting materials - definitiveApr 18, 2001View HTMLDownload DOCDownload PDFDownload XLS
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 20, 2001View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 14, 2001View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2001View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2001View HTMLDownload DOCDownload PDF
424B2Form of prospectus filed in connection with primary offering of securities on a delayed basisJan 31, 2001View HTMLDownload DOCDownload PDF
S-3/APre-effective amendment to an S-3 filingJan 29, 2001View HTMLDownload DOCDownload PDF
S-3/APre-effective amendment to an S-3 filingJan 11, 2001View HTMLDownload DOCDownload PDF
1-25      26-35

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information